Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LVR013
MIFTS: 77

Liver Disease

Categories: Blood diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Metabolic diseases, Nephrological diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Liver Disease

About this section

MalaCards integrated aliases for Liver Disease:

Name: Liver Disease 39 12 15 17
Liver Diseases 56 44 45 74
Liver Dysfunction 56 74
Liver Failure 56 74
Abnormality of the Liver 30
Disorder of Liver 12
Hepatic Disorder 12
Hepatic Failure 30
Hepatic Disease 15

Classifications:

MalaCards categories:
Global: Metabolic diseases Genetic diseases Rare diseases
Anatomical: Gastrointestinal diseases Endocrine diseases Liver diseases Nephrological diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:409
ICD9CM 36 573.9
MeSH 45 D008107
NCIt 51 C3196
SNOMED-CT 69 62857009
Sources

Summaries for Liver Disease

About this section
MedlinePlus : 44 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. There are many kinds of liver diseases: Diseases caused by viruses, such as hepatitis A, hepatitis B, and hepatitis C Diseases caused by drugs, poisons, or too much alcohol. Examples include fatty liver disease and cirrhosis. Liver cancer Inherited diseases, such as hemochromatosis and Wilson disease Symptoms of liver disease can vary, but they often include swelling of the abdomen and legs, bruising easily, changes in the color of your stool and urine, and jaundice, or yellowing of the skin and eyes. Sometimes there are no symptoms. Tests such as imaging tests and liver function tests can check for liver damage and help to diagnose liver diseases.

MalaCards based summary : Liver Disease, also known as liver diseases, is related to fatty liver disease and nonalcoholic fatty liver disease, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Liver Disease is MEG3 (Maternally Expressed 3), and among its related pathways/superpathways are Metabolism and Selenium Micronutrient Network. The drugs Fentanyl and Midazolam have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 77 Liver disease (also called hepatic disease) is a type of damage to or disease of the... more...

Sources

Related Diseases for Liver Disease

About this section

Diseases in the Liver Disease family:

Liver Failure, Infantile, Transient Infantile Liver Failure Syndrome 1
Infantile Liver Failure Syndrome 2 Acute Liver Failure

Diseases related to Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1088)
# Related Disease Score Top Affiliating Genes
1 fatty liver disease 34.7 ADIPOQ CYP2E1 INS PNPLA3 SLC17A5 TNF
2 nonalcoholic fatty liver disease 34.7 ADIPOQ INS KRT18 PNPLA3
3 polycystic liver disease 34.7 ALB GANAB PKHD1 PRKCSH
4 polycystic kidney disease 2 with or without polycystic liver disease 34.4 GANAB PKHD1 PRKCSH
5 fatty liver disease, nonalcoholic 1 34.4 ADIPOQ GPT INS KRT18 SLC17A5
6 alcoholic hepatitis 33.3 ALB CYP2E1 F2 GPT KRT18 SLC17A5
7 nonalcoholic steatohepatitis 33.0 ADIPOQ CYP2E1 F2 GPT INS KRT18
8 wilson disease 32.7 ALB F2 GPT
9 cholangitis, primary sclerosing 32.5 ABCB4 ALB DLAT GPT
10 acute liver failure 32.3 ALB F2 GPT SLC17A5
11 sclerosing cholangitis 32.3 ABCB11 ABCB4 ALB TNF
12 hepatic encephalopathy 32.3 ALB F2 GPT SLC17A5 TNF
13 congenital hepatic fibrosis 32.1 PKHD1 SLC17A5
14 hepatitis 32.0 F2 GPT KRT18 SLC17A5 TNF
15 autoimmune hepatitis 31.9 DLAT F2 GPT
16 bile duct disease 31.8 ABCB11 ABCB4 ALB F2 GPT
17 cryptogenic cirrhosis 31.8 F2 KRT18
18 cholestasis, progressive familial intrahepatic, 4 31.7 ABCB11 ABCB4
19 hepatitis b 31.6 ALB F2 GPT SLC17A5 TNF
20 diabetes mellitus, noninsulin-dependent 31.6 ADIPOQ ALB GPT INS SLC17A5 TNF
21 alcoholic liver cirrhosis 31.5 ALB CYP2E1 F2 PNPLA3 SLC17A5
22 portal hypertension 31.3 ALB F2 GPT PKHD1 TNF
23 hepatic coma 31.3 ALB F2 GPT
24 kidney disease 31.2 ADIPOQ ALB GANAB INS PKHD1
25 hepatitis a 31.1 ALB F2 GPT SERPINA1 TNF
26 viral hepatitis 31.1 ALB F2 GPT KRT18 SERPINA1 SLC17A5
27 sleep apnea 31.1 ADIPOQ INS TNF
28 cholestasis 31.0 ABCB11 ABCB4 F2 GPT HSD3B7
29 arteries, anomalies of 31.0 ADIPOQ ALB INS TNF
30 alcohol abuse 31.0 CYP2E1 GPT SLC17A5
31 infantile liver failure syndrome 1 31.0 ALB F2 FAH GPT SLC17A5
32 hepatitis e 30.9 ALB F2 GPT TNF
33 body mass index quantitative trait locus 11 30.9 ADIPOQ CYP2E1 GPT INS PNPLA3 TNF
34 atherosclerosis susceptibility 30.9 ADIPOQ INS TNF
35 peritonitis 30.8 ALB F2 TNF
36 cholangitis 30.8 ABCB11 ABCB4 ALB DLAT F2 GPT
37 cholelithiasis 30.7 ABCB4 ALB GPT
38 liver cirrhosis 30.7 ADIPOQ ALB CYP2E1 F2 GPT KRT18
39 dengue hemorrhagic fever 30.6 ALB F2 TNF
40 obstructive jaundice 30.6 ALB F2 GPT SLC17A5 TNF
41 scrub typhus 30.6 GPT SLC17A5 TNF
42 bilirubin metabolic disorder 30.5 ALB F2 GPT SLC17A5
43 hemorrhagic fever 30.5 ALB F2 GPT TNF
44 schistosomiasis 30.5 ALB F2 TNF
45 endocarditis 30.4 ALB F2 TNF
46 pyridoxine deficiency 30.4 GPT SLC17A5
47 vascular disease 30.3 ADIPOQ ALB F2 INS TNF
48 antipyrine metabolism 30.3 ALB F2
49 kwashiorkor 30.2 ALB F2 GPT SLC17A5
50 apnea, obstructive sleep 30.2 ADIPOQ INS TNF

Comorbidity relations with Liver Disease via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hepatic Encephalopathy Ischemic Heart Disease
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Liver Disease:



Diseases related to Liver Disease
Sources

Symptoms & Phenotypes for Liver Disease

About this section

UMLS symptoms related to Liver Disease:


nausea and vomiting, constipation, abdominal pain, diarrhea, hepatosplenomegaly, icterus, dyspepsia, heartburn, gastrointestinal gas, digestive system symptom, liver tender, abnormal bruising

MGI Mouse Phenotypes related to Liver Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.07 ABCB11 ABCB4 ADIPOQ ALB CYP2E1 F2
2 growth/size/body region MP:0005378 10.06 ABCB11 ABCB4 ADIPOQ F2 FAH HSD3B7
3 liver/biliary system MP:0005370 9.97 ABCB11 ABCB4 ADIPOQ ALB CYP2E1 FAH
4 digestive/alimentary MP:0005381 9.91 ABCB4 ALB F2 HSD3B7 INS PKHD1
5 mortality/aging MP:0010768 9.77 ABCB11 ADIPOQ ALB CYP2E1 F2 FAH
6 neoplasm MP:0002006 9.1 ABCB4 ADIPOQ ALB CYP2E1 FAH TNF
Sources

Drugs & Therapeutics for Liver Disease

About this section

Drugs for Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1394)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable,Early Phase 1 437-38-7 3345
2
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59467-70-8 4192
3
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 2078-54-8 4943
4
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1406-66-2 14986
5
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
6
Telmisartan Approved, Investigational Phase 4,Phase 1 144701-48-4 65999
7
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
8
Amlodipine Approved Phase 4,Phase 1 88150-42-9 2162
9
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3 141758-74-9 15991534
10
Insulin glargine Approved Phase 4,Phase 2 160337-95-1
11
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 7440-66-6 32051
12
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 128-13-2 31401
13
Atorvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 134523-00-5 60823
14
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134678-17-4 60825
15
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 142217-69-4 153941
16 Orange Approved Phase 4,Phase 2,Not Applicable
17
Glucagon Approved Phase 4,Phase 2,Not Applicable 16941-32-5
18
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 57-27-2 5288826
19
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 143491-57-0 60877
20
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 142340-99-6 60871
21
Gabapentin Approved, Investigational Phase 4,Phase 3,Not Applicable 60142-96-3 3446
22
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 64-17-5 702
23
Alprostadil Approved, Investigational Phase 4,Phase 2,Phase 1 745-65-3 149351 5280723
24
Sargramostim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 123774-72-1, 83869-56-1
25
glycyrrhizin Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1405-86-3 3495
26
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
27
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492 6473866
28
Ezetimibe Approved Phase 4,Phase 2,Phase 1 163222-33-1 150311
29
Magnesium oxide Approved Phase 4 1309-48-4 14792
30
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 198153-51-4 5360545
31
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 36791-04-5 37542
32
Insulin glulisine Approved Phase 4 207748-29-6
33
Lactulose Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4618-18-2 11333
34
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 657-24-9 14219 4091
35
Liraglutide Approved Phase 4,Phase 3,Phase 2 204656-20-2 44147092
36
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3424-98-4 159269
37
tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 1401-55-4
38
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 94-09-7, 1994-09-7 2337
39
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55981-09-4 41684
40
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
41
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 80621-81-4 6436173 46783403
42
Erythromycin Approved, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 114-07-8 12560 441411
43
Simvastatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 79902-63-9 54454
44
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99210-65-8, 215647-85-1
45
Milk thistle Approved, Experimental, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 65666-07-1
46
Mycophenolic acid Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 24280-93-1 446541
47
Propranolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 525-66-6 4946
48
Nadolol Approved Phase 4,Phase 3 42200-33-9 39147
49
Carvedilol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 72956-09-3 2585
50
Spironolactone Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52-01-7, 1952-01-7 5833

Interventional clinical trials:

(show top 50) (show all 8674)
# Name Status NCT ID Phase Drugs
1 Prospective Validation of a Plasma Transfusion Dosing Algorithm in Patients With Chronic Liver Disease Unknown status NCT02366845 Phase 4
2 Randomised Controlled Study of Popofol Versus Midazolam as Sedation in Endoscopy With Advanced Liver Disease. Unknown status NCT03063866 Phase 4 Propofol;Midazolam;Fentanyl
3 Branched-chain Amino Acid (BCAA) on Progression of Advanced Liver Disease Unknown status NCT02837302 Phase 4 Livact
4 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
5 Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
6 The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver Unknown status NCT01956825 Phase 4
7 Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes Unknown status NCT02303730 Phase 4 Exenatide;insulin glargine
8 Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases Unknown status NCT01337440 Phase 4 UDCA;Sitagliptin
9 Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
10 Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients Unknown status NCT00823550 Phase 4 Entecavir;Lamivudine
11 The Orange-III Trial: Optimised Recovery With Movicol® Preoperatively Within an Enhanced Recovery Programme Unknown status NCT01429779 Phase 4 Movicol
12 Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography Unknown status NCT00155376 Phase 4 morphine and glucagon
13 Effect of Probiotics on Gut-Liver Axis of Alcoholic Hepatitis Unknown status NCT02335632 Phase 4 Probiotics (Lacidofil®);Placebo
14 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
15 Emtricitabine for Naive Chinese Chronic Hepatitis B Patients Unknown status NCT02327663 Phase 4 Emtricitabine
16 Treatment for Alcohol Dependence With Gabapentin Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
17 Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients Unknown status NCT02210715 Phase 4 Isentress.
18 RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure Unknown status NCT02331745 Phase 4 Granulocyte colony-stimulating factor;standard treatment
19 A Study of Thymoglobulin and Tacrolimus in Liver Transplant Unknown status NCT00564538 Phase 4 anti-thymocyte globulin (rabbit);tacrolimus
20 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
21 Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients Unknown status NCT02327715 Phase 4 Emtricitabine
22 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
23 Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients Unknown status NCT02327689 Phase 4 Emtricitabine plus adefovir dipivoxil
24 Magnesium in Liver Cirrhosis Unknown status NCT01894867 Phase 4
25 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4 Entecavir;placebo
26 Telaprevir in Genotype 3 HCV Unknown status NCT02087111 Phase 4 Telaprevir;40 Kd Pegylated interferon alfa 2a;Ribavirin
27 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
28 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
29 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
30 Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4 metformin
31 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
32 Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
33 Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP) Unknown status NCT00761098 Phase 4 Standard Care;Experimental
34 Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
35 Efficacies of Entecavir Add on HBeAg Positive Patients With HBV DNA Positive During Peginterferon Alpha 2a Treatment Unknown status NCT02368288 Phase 4 entecavir
36 HIV Persistence and Viral Reservoirs Unknown status NCT01025427 Phase 4 Raltegravir, tenofovir/emtricitabine
37 Efficacies of Entecavir Add on HBeAg Negative Patients With HBV DNA Positive During Peginterferon Alpha 2a Treatment Unknown status NCT02365402 Phase 4 Entecavir
38 Efficacy of Peginterferon Alpha 2a Therapy in Chronic Hepatitis B Patients Being Treated With Nucleoside(Acid) Analogues Unknown status NCT02362490 Phase 4 peginterferon alpha 2a
39 Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE) Unknown status NCT00655967 Phase 4 Acamprosate (Campral);Acamprosate
40 Rifaximin Versus Lactulose in Renal Failure Unknown status NCT00748904 Phase 4 Rifaximin;Lactulose
41 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4 Erythromycin
42 Influence of CYP3A5 Polymorphism on Liver Function Abnormality and the Trough Level Change After Conversion Unknown status NCT02882113 Phase 4 Advagraf
43 Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc) Unknown status NCT00736463 Phase 4 Simvastatin;Atorvastatin 80 mg
44 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4 Metformin
45 A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD) Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
46 Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Unknown status NCT02757170 Phase 4
47 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
48 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
49 Complex Imaging Assessment of Steatosis Unknown status NCT02669641 Phase 4
50 TO Compare the Triple Drug Therapy and Dual Therapy . Unknown status NCT02075242 Phase 4 Mycophenolate Mofetil;Tacrolimus

Search NIH Clinical Center for Liver Disease

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Liver Disease cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Liver Disease:
Adult stem cell therapy for liver insufficiency
Bone marrow-derived mesenchymal stem cells for treatment of liver failure
Embryonic/Adult Cultured Cells Related to Liver Disease:
Peripheral blood-derived hematopoietic stem cells PMIDs: 18181952 16556705 22121493
Bone marrow-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: liver diseases

Sources

Genetic Tests for Liver Disease

About this section

Genetic tests related to Liver Disease:

# Genetic test Affiliating Genes
1 Hepatic Failure 30
2 Abnormality of the Liver 30
Sources

Anatomical Context for Liver Disease

About this section

MalaCards organs/tissues related to Liver Disease:

42
Liver, Testes, Kidney, T Cells, Bone, Lung, Heart
Sources

Publications for Liver Disease

About this section

Articles related to Liver Disease:

(show top 50) (show all 13859)
# Title Authors Year
1
Recurrent acute pancreatitis in a patient with both gallbladder and cystic duct agenesis and polycystic liver disease. ( 30792840 )
2019
2
Nonalcoholic Fatty Liver Disease Aggravated the Severity of Acute Pancreatitis in Patients. ( 30805370 )
2019
3
Association of TM6SF2 rs58542926 gene polymorphism with the risk of non-alcoholic fatty liver disease and colorectal adenoma in Chinese Han population. ( 30727943 )
2019
4
Liver fibrosis is associated with risk for colorectal adenoma in patients with nonalcoholic fatty liver disease. ( 30732129 )
2019
5
The association between nonalcoholic fatty liver disease and risk of colorectal adenoma and cancer incident and recurrence: a meta-analysis of observational studies. ( 30791768 )
2019
6
Liver disease in adults with severe alpha-1-antitrypsin deficiency. ( 30680526 )
2019
7
Alpha-1 antitrypsin deficiency liver disease, mutational homogeneity modulated by epigenetic heterogeneity with links to obesity. ( 30681738 )
2019
8
Comparison of variation in frequency for SNPs associated with asthma or liver disease between Estonia, HapMap populations and the 1000 genome project populations. ( 30659741 )
2019
9
Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta-analysis. ( 30657626 )
2019
10
Interatrial septal fat thickness and left atrial stiffness are mechanistic links between nonalcoholic fatty liver disease and incident atrial fibrillation. ( 30548700 )
2019
11
Development of colorectal cancer predicts increased risk of subsequent hepatocellular carcinoma in patients with alcoholic liver disease: case-control and cohort study. ( 30824851 )
2019
12
A HSD17B13 variant protects from hepatocellular carcinoma development in alcoholic liver disease. ( 30908678 )
2019
13
Improving survival in patients with hepatocellular carcinoma related to chronic hepatitis C and B but not in those related to non-alcoholic steatohepatitis or alcoholic liver disease: a 20-year experience from a national programme. ( 30908822 )
2019
14
18F-FDG PET/CT AS AN ASSESSMENT TOOL OF HEPATOCELLULAR CARCINOMA SECONDARY TO NON-ALCOHOLIC FATTY LIVER DISEASE DEVELOPMENT IN EXPERIMENTAL MODEL. ( 30892403 )
2019
15
Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. ( 30842500 )
2019
16
High-Quality Diets Are Associated With Reduced Risk of Hepatocellular Carcinoma and Chronic Liver Disease: The Multiethnic Cohort. ( 30859154 )
2019
17
Phytosterols and Triterpenoids for Prevention and Treatment of Metabolic- related Liver Diseases and Hepatocellular Carcinoma. ( 30806308 )
2019
18
Soluble fibers improve metabolic syndrome but may cause liver disease and hepatocellular carcinoma. ( 30762890 )
2019
19
Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment. ( 30791221 )
2019
20
Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease. ( 30791782 )
2019
21
Predictors of Radiation-Induced Liver Disease in Eastern and Western Patients with Hepatocellular Carcinoma Undergoing Proton Beam Therapy. ( 30797890 )
2019
22
Hyaluronan histochemistry-A potential new tool to assess the progress of liver disease from simple steatosis to hepatocellular carcinoma. ( 30689936 )
2019
23
Association and interaction between model for end-stage liver disease score and minimally invasive treatment with regard to mortality of patients with hepatitis B virus-associated hepatocellular carcinoma and portal vein tumor thrombi. ( 30655746 )
2019
24
Hepatocellular carcinoma in the setting of alcohol-related liver disease. ( 30658729 )
2019
25
Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis. ( 30668889 )
2019
26
Among Medicare Patients With Hepatocellular Carcinoma, Non-alcoholic Fatty Liver Disease is the Most Common Etiology and Cause of Mortality. ( 30672817 )
2019
27
Role of non-coding RNAs in liver disease progression to hepatocellular carcinoma. ( 30610616 )
2019
28
Liver Resection for Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: a Multicenter Propensity Matching Analysis with HBV-HCC. ( 30617773 )
2019
29
Racial Disparities in Liver Transplantation for Hepatocellular Carcinoma Are Not Explained by Differences in Comorbidities, Liver Disease Severity, or Tumor Burden. ( 30619994 )
2019
30
Diabetic Retinopathy as a Risk Factor Associated with the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. ( 30625487 )
2019
31
Role of MicroRNAs in the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. ( 30312023 )
2019
32
Nonalcoholic fatty liver disease is associated with breast cancer in nonobese women. ( 30686716 )
2019
33
Aromatase Inhibitors and Newly Developed Nonalcoholic Fatty Liver Disease in Postmenopausal Patients with Early Breast Cancer: A Propensity Score-Matched Cohort Study. ( 30679317 )
2019
34
Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis. ( 30872395 )
2019
35
Metabolic liver diseases presenting with neonatal cholestasis: at the crossroad between old and new paradigms. ( 30693370 )
2019
36
Crohn's Disease is Associated with an Increased Prevalence of Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study using Magnetic Resonance Proton Density Fat Fraction Mapping. ( 30876963 )
2019
37
Case report: Cholecystoduodenostomy for cholestatic liver disease in a premature infant with cystic fibrosis and short gut syndrome. ( 30857526 )
2019
38
Accuracy of Transient Elastography Data Combined With APRI in Detection and Staging of Liver Disease in Pediatric Patients With Cystic Fibrosis. ( 30880274 )
2019
39
A multi-disciplinary approach to pre and post-transplant management of cystic fibrosis associated liver disease. ( 30697907 )
2019
40
SERPINA1 Z allele is associated with cystic fibrosis liver disease. ( 30739910 )
2019
41
Modifier genes in cystic fibrosis-related liver disease. ( 30585791 )
2019
42
Renal Dysfunction in Patients With Nonalcoholic Fatty Liver Disease is Related to the Presence of Diabetes Mellitus and Severity of Liver Disease. ( 30765935 )
2019
43
SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review. ( 30788048 )
2019
44
Letter to Editor: Role of Pharmacotherapy in Patients With Coexisting Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. ( 30734333 )
2019
45
Non-alcoholic fatty liver disease is associated with low-grade albuminuria in men without diabetes mellitus. ( 30745809 )
2019
46
Fatal case of necrotising fasciitis due to Vibrio vulnificus in a patient with alcoholic liver disease and diabetes mellitus. ( 30659010 )
2019
47
Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study. ( 30682184 )
2019
48
The utility of ezetimibe therapy in nonalcoholic fatty liver disease. ( 30840809 )
2019
49
Systems Genetics of Hepatic Metabolome Reveals Octopamine as a Target for Non-Alcoholic Fatty Liver Disease Treatment. ( 30842494 )
2019
50
Current treatment options for nonalcoholic fatty liver disease. ( 30844893 )
2019
Sources

Variations for Liver Disease

About this section
Sources

Expression for Liver Disease

About this section
Search GEO for disease gene expression data for Liver Disease.
Sources

Pathways for Liver Disease

About this section

Pathways related to Liver Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Metabolism 67
Show member pathways
 13.66 ABCB11 ABCB4 ADIPOQ ALB CYP2E1 DLAT
2
Selenium Micronutrient Network 1
Show member pathways
 11.96 ALB F2 INS TNF
3
Type II diabetes mellitus 38 1
Show member pathways
 11.53 ADIPOQ INS TNF
4
Adipogenesis 1
11.38 ADIPOQ INS PNPLA3 TNF
5
FOXA2 and FOXA3 transcription factor networks 1
10.98 ALB F2 INS
6
Farnesoid X Receptor Pathway 1
10.71 ABCB11 ABCB4
7
Cori Cycle 1
10.61 GPT INS
8
Nuclear Receptors in Lipid Metabolism and Toxicity 1
10.34 ABCB11 ABCB4 CYP2E1
Sources

GO Terms for Liver Disease

About this section

Cellular components related to Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.87 ADIPOQ ALB CYP2E1 GANAB HSD3B7 PRKCSH
2 extracellular exosome GO:0070062 9.85 ABCB11 ABCB4 ALB F2 FAH GANAB
3 intercellular canaliculus GO:0046581 9.26 ABCB11 ABCB4
4 endoplasmic reticulum lumen GO:0005788 9.1 ALB F2 GANAB INS PRKCSH SERPINA1
5 glucosidase II complex GO:0017177 8.96 GANAB PRKCSH

Biological processes related to Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to bacterium GO:0009617 9.65 ADIPOQ CYP2E1 SLC17A5
2 negative regulation of lipid catabolic process GO:0050995 9.46 INS TNF
3 positive regulation of cellular protein metabolic process GO:0032270 9.43 ADIPOQ INS
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.43 F2 INS TNF
5 negative regulation of gluconeogenesis GO:0045721 9.4 ADIPOQ INS
6 N-glycan processing GO:0006491 9.37 GANAB PRKCSH
7 cellular protein metabolic process GO:0044267 9.35 ALB F2 INS PRKCSH SERPINA1
8 acute-phase response GO:0006953 9.33 F2 INS SERPINA1
9 regulation of protein secretion GO:0050708 9.32 INS TNF
10 glucose metabolic process GO:0006006 8.92 ADIPOQ DLAT INS TNF

Molecular functions related to Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 8.8 INS SERPINA1 TNF
Sources

Sources for Liver Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....